Effects of artificial musk on hyperlipemia in rats

Abstract

Abstract: AIM: To investigate the effect of artificial musk on hyperlipermia in rats.METHODS: SD rats were randomly divided into six groups: control group, model group, simvastatin group, artificial musk low,middle and high groups. The fatty emulsion were given to model group and treated groups, but none to control group. The levels of total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C) and high density lipoprotein cholesterol(HDL-C) were measured . The levels of serum CRP,ET-1 and TNF-α were determined by double-antibody sandwich ELISA.RESULTS: The function in reducing the content of serum TC,TG were different between artificial groups and model group(P<0.05). Artificial musk high dose group decreased the serum levels of CRP,ET-1 and TNF-α(P<0.05).CONCLUSION: Artificial musk can improve hyperlipermia in rats.

Key words: Artificial musk, Hyperlipermia, Lipid

CLC Number:

R965.2

LI Hai-tao, ZHU Xue-jing, WU Qi-biao. Effects of artificial musk on hyperlipemia in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(9): 1008-1011.

References

[1] 朱雪晶,李海涛,吴其标,等.天然、人工麝香对心血管系统作用研究进展[J].南京中医药大学学报,2009,25(4):316-317.
[2] 朱雪晶,李海涛,喻斌,等.人工麝香对抗动物心肌缺血的作用[J].中国药理学通报,2009,25(7):951-954.
[3] 刘明,董超仁,苏静怡.一种简单实用的大鼠高脂血症模型[J].中国药理学通报,1989,5(2):119-120.
[4] 章义利,周秀云,应斌宇,等.大鼠动脉粥样硬化模型的建立方法[J].温州医学院学报,2007,37(4):331-332.
[5] 闫莉萍,陈舜宏,陈伟民,等.葛根素对膳食诱导的高胆固醇血症大鼠的血脂调节作用[J].中国临床药理学与治疗学,2006,11(5):574-577.
[6] 肖方喜,陈璐璐,孙晖,等.白藜芦醇对高脂喂养诱导的脂肪肝大鼠血清TNF-α含量的影响[J].中国康复,2008,23(6):377-379.
[7] 邓瑞春,张文生,杨洪军,等.柿叶乙醇提取物治疗大鼠高脂血症的实验研究[J].中国中医药信息杂志,2004,11(6):493-494.
[8] Partrick L,Uzick M.Cardiovascular disease:HMG CoA reductase inhibitors, alphatocophero, l red yeast rice, and olide oil polyphenols. A review of the literature [J]. Altern Med Rev, 2001,6(3):248-271.
[9] 张梅,温进坤,陈兴,等.冠心Ⅱ号对动脉粥样硬化大鼠血脂、TNF-α、NO及TXA₂/PGI₂影响的实验研究[J].中国中医药科技,2008,15(1):20-21.
[10] 李宝华,郑广娟,张文高,等.软脉降脂胶囊对实验性高脂血症大鼠血脂及MDA、SOD、NO的影响[J].中西医结合心脑血管病杂志,2004,2(4):220-222.
[11] 郝吉福,程怡.麝香的药理学研究概况[J].时珍国医国药,2004,15(4):248-249.
[12] 朱莉,董秋立,刘忠志,等.麝香保心丸对实验性动脉粥样硬化兔LOX-1蛋白及基因表达的影响[J].上海中医药大学学报,2008,22(2):43-45.
[13] 张琼,张向农,涂秀华.麝香心痛宁片治疗冠心病心绞痛(气滞血瘀证)的临床研究[J].中国临床药理学与治疗学,2005,10(9):1069-1072.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHAO Lu, LI Fuyong, WEN Binhong, LI Daowei. Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 671-675.
[3]	CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei. Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248.
[4]	LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong. Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
[5]	TANG Zizhao, NIE Fangqin, YAN Xin, FU Yangxia, HUANG Jun, WANG Xia, GUO Ren. Effect of Atglistatin on PA-induced VSMCs proliferation and ATGL expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 29-35.
[6]	WANG Xin, LIU Weiying, WU Chen, KAI Jinjun, LIANG Xuejie, CHANG Yingxuan. Metformin regulates AMPK/SREBP-1 pathway and its clinical application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1049-1054.
[7]	WANG Kai, SONG Min, SONG Zhijing, LI Jinyi. Mechanism of vascular endothelial cells ferroptosis in cervical spondylosis of vertebral artery type [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 588-594.
[8]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Evinacumab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
[9]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Inclisiran [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
[10]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
[11]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[12]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[13]	LI Wenxia, FANG Liuyuan, QIAN Shenxian. Mechanism of ferroptosis and its research progress in lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 314-321.
[14]	ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli. Ferroptosis regulatory signaling pathway and its research progress in related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
[15]	GUO Yuting, LI Shanshan, LI Qinglin. Tianma Gouteng Yin protects rotenone-induced PC12 cell damage by inhibiting ferroptosis-lipid metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 8-14.